Trial · NCT03373383
Adverse events660
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 660
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Placebo Treatment Period (SS) | 7 | 83 | 7 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 50mg BID Treatment Period (SS) | 3 | 81 | 3 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 100mg BID Treatment Period (SS) | 2 | 83 | 2 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 200mg BID Treatment Period (SS) | 3 | 82 | 3 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 400mg BID Treatment Period (SS) | 4 | 81 | 5 |
| other | Vertigo | Ear and labyrinth disorders | Placebo Conversion Period (SS) | 1 | 69 | 1 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 50mg BID Conversion Period (SS) | 0 | 64 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 100mg BID Conversion Period (SS) | 0 | 66 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 200mg BID Conversion Period (SS) | 0 | 55 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 400mg BID Conversion Period (SS) | 0 | 57 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Placebo Taper and SFU Period (SS) | 0 | 9 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 50mg BID Taper and SFU Period (SS) | 0 | 14 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 100mg BID Taper and SFU Period (SS) | 0 | 11 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 200mg BID Taper and SFU Period (SS) | 0 | 24 | 0 |
| other | Vertigo | Ear and labyrinth disorders | Padsevonil 400mg BID Taper and SFU Period (SS) | 0 | 22 | 0 |
| other | Nausea | Gastrointestinal disorders | Placebo Treatment Period (SS) | 7 | 83 | 7 |
| other | Nausea | Gastrointestinal disorders | Padsevonil 50mg BID Treatment Period (SS) | 4 | 81 | 4 |
| other | Nausea | Gastrointestinal disorders | Padsevonil 100mg BID Treatment Period (SS) | 7 | 83 | 7 |
| other | Nausea | Gastrointestinal disorders | Padsevonil 200mg BID Treatment Period (SS) | 2 | 82 | 3 |
| other | Nausea | Gastrointestinal disorders | Padsevonil 400mg BID Treatment Period (SS) | 7 | 81 | 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03373383/events